CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.

Ten Chinese biotechs raised at least a combined $221m in venture capital and private equity deals after the turn of the year.

Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.

Hemab’s series B financing will fund its lead program, currently in Phase I/II for Glanzmann thrombasthenia, as it moves into pivotal testing plus at least one other asset heading into the clinic.